Latest news

• Moderna launches COVID-19 vaccine booster study to address new variants

  BNT162b2-vaccinated blood samples.

• Pfizer/BioNTech’s COVID-19 vaccine neutralises Brazil variant, suggests study

  The study, conducted by scientists from Pfizer and BioNTech alongside researchers from the University of Texas Medical Branch, used blood samples from people who had received the BNT162b2 vaccine. ... However, neutralisation of the South Africa variant,

• UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people

  The research, conducted in Israel, used data from Clalit Health Services to evaluate the effectiveness of the Pfizer/BioNTech vaccine, BNT162b2. ... The researchers measured vaccine effectiveness for the study outcomes at days 14 to 20 after the first

• Pfizer/BioNTech vaccine is 94% effective after second dose, major real-world study finds

  The research, conducted in Israel, used data from Clalit Health Services to evaluate the effectiveness of the Pfizer/BioNTech vaccine, also known as BNT162b2. ... The researchers measured vaccine effectiveness for the study outcomes at days 14 to 20

• Researchers suggest delaying second dose of Pfizer/BioNTech jab to protect more people

  They found that, even before receiving the second dose, the Pfizer/BioNTech vaccine – also known as BNT162b2 – was ‘highly efficacious’ with a vaccine efficacy of 92.6%. ... BioNTech’s chief executive Ugur Sahin told Sky News that the second